Document is current
Any future updates will be listed below
-
Authors
Olive, Rachel Rowan
Kellermann, Vanessa
Said, Olena
Filiz, Ece Sengun
Treasure, Janet
Schmidt, Ulrike
Bentley, Jessica
Khor, Joel W. T.
Simic, Mima
Nicholls, Dasha
Himmerich, Hubertus
Lawrence, Vanessa
-
Funding
Funding for this research was provided by:
National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre (NETSCC) Health Technology Assessment (HTA) Programme (NIHR130780)
NIHR Imperial Biomedical Research Centre
- License Information
-
More Information
Article History
Received: 14 February 2025
Accepted: 29 August 2025
First Online: 16 October 2025
Declarations
:
: The study was approved by Health and Social Care Research Ethics Committee B (Reference 22/NI/0010) and the Health Research Authority (HRA) on 11 April 2022.
: Not applicable.
: HH will receive funding from the UK Medical Research Council (MRC) for a double-blinded randomised controlled feasibility trial to test oral ketamine in people with anorexia nervosa and depression; the trial will start in 2025. HH is the principal investigator of a phase 2 clinical trial investigating the efficacy and safety of investigational COMP360 psilocybin treatment in anorexia nervosa.
